We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amdocs posted Q4 EPS of $1.83, topping estimates and rising 7.6% year over year.
Revenues fell 9% annually to $1.15B but grew 2.8%, excluding phased-out activities.
FY2026 outlook calls for 1.7-5.7% revenue growth and 4-8% EPS expansion.
Amdocs Limited (DOX - Free Report) reported better-than-expected fourth-quarter fiscal 2025 results. The company posted non-GAAP earnings of $1.83 per share, which came above the midpoint of the management’s guidance of $1.79-$1.85 and increased 7.6% year over year. The figure also exceeded the Zacks Consensus Estimate of $1.82.
In the trailing four quarters, DOX’s earnings outpaced the Zacks Consensus Estimate thrice while matching once, with an average surprise of 1.6%.
Amdocs’ fourth-quarter revenues of $1.15 billion surpassed the consensus mark of $1.14 billion. However, compared with the year-ago quarter, revenues were down 9% on a reported basis due to the phase-out of certain business activities. Excluding the effect of phase-out business activities, revenues were up 2.8% year over year in pro forma constant currency.
Amdocs reported a decline in revenues across North America, Europe and the Rest of the World (RoW). North America reported revenues of $762 million (66% of total revenues), which decreased 8.8% year over year. RoW revenues (18% of total revenues) dropped 5% year over year to $208 million.
Europe revenues (16% of total revenues) of $180 million decreased 0.8% year over year. Our model estimates for North America, RoW and Europe were pinned at $743.4 million, $221.2 million and $176.7 million, respectively.
Managed services revenues rose 3.7% year over year to $748.3 million. The company ended the fourth quarter of fiscal 2025 with a 12-month backlog of $4.19 billion, up $40 million sequentially. Our model estimates for managed services revenues and backlog were pegged at $731.5 million and $4.07 billion, respectively.
The non-GAAP operating income increased 5% year over year to $248.1 million, while the operating margin expanded 290 basis points (bps) to 21.6%.
Amdocs’ Balance Sheet & Cash Flow
Amdocs had cash and short-term investments of $325 million as of Sept. 30, 2025 compared with $342.5 million as of June 30, 2025. Long-term debt was $646.9 million as of Sept. 30, 2025, almost flat to the June 30, 2025 level of $646.7 million.
During the fourth quarter, it generated an operating cash flow of $229.8 million and a free cash flow of $198.6 million. In full fiscal 2025, it generated operating cash flow and free cash flow of $749.1 million and $645.1 million, respectively.
Amdocs Initiates Guidance for Q1 & FY2026
Amdocs initiated guidance for the first quarter and fiscal 2026. For the first quarter, the company expects revenues to be in the band of $1.135-$1.175 billion (midpoint $1.155 billion). The Zacks Consensus Estimate for revenues is pegged at $1.14 billion, suggesting a year-over-year increase of 3%.
Amdocs expects non-GAAP earnings per share to be between $1.73 and $1.79. The Zacks Consensus Estimate for earnings is pegged at $1.86 per share, indicating a year-over-year rise of 12%.
For fiscal 2026, Amdocs expects revenues to grow in the 1.7-5.7% range. The Zacks Consensus Estimate for revenues is pegged at $4.7 billion, suggesting a year-over-year increase of 3.8%.
The on-GAAP operating margin is anticipated to be in the range of 21.3-21.9% for fiscal 2026. Non-GAAP earnings per share are expected to grow in the band of 4-8%. The Zacks Consensus Estimate for earnings is pegged at $7.60 per share, indicating a year-over-year rise of 8.9%.
The company expects free cash flow between $710 million and $730 million.
The Zacks Consensus Estimate for Reddit’s full-year 2025 earnings is pegged at $2.35 per share, revised upward by 23.7% over the past 30 days and suggests a year-over-year increase of 170.6%. Reddit shares have soared 27.4% year to date.
The Zacks Consensus Estimate for Amphenol’s full-year 2025 earnings has been revised upward to $3.22 per share from $3.03 per share 30 days ago, implying 70.4% year-over-year growth. Amphenol shares have surged 106.6% year to date.
The Zacks Consensus Estimate for DocuSign’s fiscal 2026 earnings has moved northward by 2 cents over the past 60 days to $3.69 per share, calling for an increase of 3.9% year over year. DocuSign shares have plunged 23.4% year to date.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amdocs Q4 Earnings Surpass Estimates, Revenues Decline Y/Y
Key Takeaways
Amdocs Limited (DOX - Free Report) reported better-than-expected fourth-quarter fiscal 2025 results. The company posted non-GAAP earnings of $1.83 per share, which came above the midpoint of the management’s guidance of $1.79-$1.85 and increased 7.6% year over year. The figure also exceeded the Zacks Consensus Estimate of $1.82.
In the trailing four quarters, DOX’s earnings outpaced the Zacks Consensus Estimate thrice while matching once, with an average surprise of 1.6%.
Amdocs’ fourth-quarter revenues of $1.15 billion surpassed the consensus mark of $1.14 billion. However, compared with the year-ago quarter, revenues were down 9% on a reported basis due to the phase-out of certain business activities. Excluding the effect of phase-out business activities, revenues were up 2.8% year over year in pro forma constant currency.
Amdocs Limited Price, Consensus and EPS Surprise
Amdocs Limited price-consensus-eps-surprise-chart | Amdocs Limited Quote
Amdocs’ Q4 Details
Amdocs reported a decline in revenues across North America, Europe and the Rest of the World (RoW). North America reported revenues of $762 million (66% of total revenues), which decreased 8.8% year over year. RoW revenues (18% of total revenues) dropped 5% year over year to $208 million.
Europe revenues (16% of total revenues) of $180 million decreased 0.8% year over year. Our model estimates for North America, RoW and Europe were pinned at $743.4 million, $221.2 million and $176.7 million, respectively.
Managed services revenues rose 3.7% year over year to $748.3 million. The company ended the fourth quarter of fiscal 2025 with a 12-month backlog of $4.19 billion, up $40 million sequentially. Our model estimates for managed services revenues and backlog were pegged at $731.5 million and $4.07 billion, respectively.
The non-GAAP operating income increased 5% year over year to $248.1 million, while the operating margin expanded 290 basis points (bps) to 21.6%.
Amdocs’ Balance Sheet & Cash Flow
Amdocs had cash and short-term investments of $325 million as of Sept. 30, 2025 compared with $342.5 million as of June 30, 2025. Long-term debt was $646.9 million as of Sept. 30, 2025, almost flat to the June 30, 2025 level of $646.7 million.
During the fourth quarter, it generated an operating cash flow of $229.8 million and a free cash flow of $198.6 million. In full fiscal 2025, it generated operating cash flow and free cash flow of $749.1 million and $645.1 million, respectively.
Amdocs Initiates Guidance for Q1 & FY2026
Amdocs initiated guidance for the first quarter and fiscal 2026. For the first quarter, the company expects revenues to be in the band of $1.135-$1.175 billion (midpoint $1.155 billion). The Zacks Consensus Estimate for revenues is pegged at $1.14 billion, suggesting a year-over-year increase of 3%.
Amdocs expects non-GAAP earnings per share to be between $1.73 and $1.79. The Zacks Consensus Estimate for earnings is pegged at $1.86 per share, indicating a year-over-year rise of 12%.
For fiscal 2026, Amdocs expects revenues to grow in the 1.7-5.7% range. The Zacks Consensus Estimate for revenues is pegged at $4.7 billion, suggesting a year-over-year increase of 3.8%.
The on-GAAP operating margin is anticipated to be in the range of 21.3-21.9% for fiscal 2026. Non-GAAP earnings per share are expected to grow in the band of 4-8%. The Zacks Consensus Estimate for earnings is pegged at $7.60 per share, indicating a year-over-year rise of 8.9%.
The company expects free cash flow between $710 million and $730 million.
DOX’s Zacks Rank and Stocks to Consider
Currently, Amdocs carries a Zacks Rank #3 (Hold).
Reddit Inc. (RDDT - Free Report) , Amphenol (APH - Free Report) and DocuSign (DOCU - Free Report) are some better-ranked stocks that investors can consider in the Zacks Computer and Technology sector. Reddit and Amphenol each sport a Zacks Rank #1 (Strong Buy) at present, while DocuSign carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Reddit’s full-year 2025 earnings is pegged at $2.35 per share, revised upward by 23.7% over the past 30 days and suggests a year-over-year increase of 170.6%. Reddit shares have soared 27.4% year to date.
The Zacks Consensus Estimate for Amphenol’s full-year 2025 earnings has been revised upward to $3.22 per share from $3.03 per share 30 days ago, implying 70.4% year-over-year growth. Amphenol shares have surged 106.6% year to date.
The Zacks Consensus Estimate for DocuSign’s fiscal 2026 earnings has moved northward by 2 cents over the past 60 days to $3.69 per share, calling for an increase of 3.9% year over year. DocuSign shares have plunged 23.4% year to date.